Binder Gwendolyn

SEC source: 0001791742-26-000002 · wk-form4_1781289457.xml · derivative · entry 1

Binder Gwendolyn · CIK 0001791742 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,500

Underlying: Common Stock · 6,500 shares

Expires 2036-06-10

F1 · derivative.exercise_date: The option will vest in 12 substantially equal monthly installments commencing on July 11, 2026, subject to the Reporting Person's Continuous Service (as defined in the company's 2021 Equity Incentive Plan, the "Plan") through the vesting dates. Any portion of the option not vested on the date of the next annual stockholder meeting will vest in full, subject to the Reporting Person's Continuous Service through such date. The option will also vest in full in the event of the Reporting Person's death, Disability (as defined in the Plan) or upon a Change in Control (as defined in the Plan).

SEC source: 0001193125-26-086135 · ownership.xml · derivative · entry 1

Binder Gwendolyn · CIK 0001791742 · President, Science & Tech.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Stock · 225,000 shares

Expires 2036-03-01

F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on March 1, 2027, with the remainder vesting in twelve substantially equal quarterly installments thereafter, subject to the reporting person's continued service on each such vesting date.

SEC source: 0001193125-26-018325 · ownership.xml · nonDerivative · entry 1

Binder Gwendolyn · CIK 0001791742 · President, Science & Tech.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,312

SEC source: 0001789769-25-000070 · wk-form4_1748560384.xml · derivative · entry 1

Binder Gwendolyn · CIK 0001791742 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,500

Underlying: Common Stock · 6,500 shares

Expires 2035-05-27

F1 · derivative.exercise_date: The option will vest in 12 substantially equal monthly installments commencing on June 28, 2025, subject to the Reporting Person's Continuous Service (as defined in the company's 2021 Equity Incentive Plan, the "Plan") through the vesting dates. Any portion of the option not vested on the date of the next annual stockholder meeting will vest in full, subject to the Reporting Person's Continuous Service through such date. The option will also vest in full in the event of the Reporting Person's death, Disability (as defined in the Plan) or upon a Change in Control (as defined in the Plan).

SEC source: 0000950170-25-074816 · ownership.xml · derivative · entry 12

Binder Gwendolyn · CIK 0001791742 · President, Science & Tech.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2034-02-28

F3 · derivative.exercise_price: The exercise price of the option is $1.92 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period", through which the Reporting Person must remain in service to the Issuer, commenced on the Repricing Date and ends upon the earliest of (i) the one-year anniversary of the Repricing Date, (ii) a Sale Event (as defined in the 2018 Plan and 2019 Plan, as applicable) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2018 Plan and 2019 Plan, as applicable) due to the Reporting Person's death or disability.

F1 · kind: On May 15, 2025, the Issuer's board of directors approved an option repricing (the "Repricing"), to be effective May 19, 2025 (the "Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan (the "2018 Plan") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan (the "2019 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-074816 · ownership.xml · derivative · entry 11

Binder Gwendolyn · CIK 0001791742 · President, Science & Tech.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 130,000 shares

Expires 2034-02-28

F1 · kind: On May 15, 2025, the Issuer's board of directors approved an option repricing (the "Repricing"), to be effective May 19, 2025 (the "Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan (the "2018 Plan") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan (the "2019 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-074816 · ownership.xml · derivative · entry 10

Binder Gwendolyn · CIK 0001791742 · President, Science & Tech.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,000

Underlying: Common Stock · 176,000 shares

Expires 2033-01-17

F3 · derivative.exercise_price: The exercise price of the option is $1.92 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period", through which the Reporting Person must remain in service to the Issuer, commenced on the Repricing Date and ends upon the earliest of (i) the one-year anniversary of the Repricing Date, (ii) a Sale Event (as defined in the 2018 Plan and 2019 Plan, as applicable) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2018 Plan and 2019 Plan, as applicable) due to the Reporting Person's death or disability.

F1 · kind: On May 15, 2025, the Issuer's board of directors approved an option repricing (the "Repricing"), to be effective May 19, 2025 (the "Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan (the "2018 Plan") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan (the "2019 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-074816 · ownership.xml · derivative · entry 9

Binder Gwendolyn · CIK 0001791742 · President, Science & Tech.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 176,000 shares

Expires 2033-01-17

F1 · kind: On May 15, 2025, the Issuer's board of directors approved an option repricing (the "Repricing"), to be effective May 19, 2025 (the "Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan (the "2018 Plan") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan (the "2019 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-074816 · ownership.xml · derivative · entry 8

Binder Gwendolyn · CIK 0001791742 · President, Science & Tech.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,000

Underlying: Common Stock · 160,000 shares

Expires 2032-01-17

F3 · derivative.exercise_price: The exercise price of the option is $1.92 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period", through which the Reporting Person must remain in service to the Issuer, commenced on the Repricing Date and ends upon the earliest of (i) the one-year anniversary of the Repricing Date, (ii) a Sale Event (as defined in the 2018 Plan and 2019 Plan, as applicable) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2018 Plan and 2019 Plan, as applicable) due to the Reporting Person's death or disability.

F1 · kind: On May 15, 2025, the Issuer's board of directors approved an option repricing (the "Repricing"), to be effective May 19, 2025 (the "Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan (the "2018 Plan") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan (the "2019 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-074816 · ownership.xml · derivative · entry 7

Binder Gwendolyn · CIK 0001791742 · President, Science & Tech.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 160,000 shares

Expires 2032-01-17

F1 · kind: On May 15, 2025, the Issuer's board of directors approved an option repricing (the "Repricing"), to be effective May 19, 2025 (the "Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan (the "2018 Plan") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan (the "2019 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-074816 · ownership.xml · derivative · entry 6

Binder Gwendolyn · CIK 0001791742 · President, Science & Tech.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2031-02-28

F3 · derivative.exercise_price: The exercise price of the option is $1.92 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period", through which the Reporting Person must remain in service to the Issuer, commenced on the Repricing Date and ends upon the earliest of (i) the one-year anniversary of the Repricing Date, (ii) a Sale Event (as defined in the 2018 Plan and 2019 Plan, as applicable) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2018 Plan and 2019 Plan, as applicable) due to the Reporting Person's death or disability.

F1 · kind: On May 15, 2025, the Issuer's board of directors approved an option repricing (the "Repricing"), to be effective May 19, 2025 (the "Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan (the "2018 Plan") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan (the "2019 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-074816 · ownership.xml · derivative · entry 5

Binder Gwendolyn · CIK 0001791742 · President, Science & Tech.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 125,000 shares

Expires 2031-02-28

F1 · kind: On May 15, 2025, the Issuer's board of directors approved an option repricing (the "Repricing"), to be effective May 19, 2025 (the "Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan (the "2018 Plan") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan (the "2019 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-074816 · ownership.xml · derivative · entry 4

Binder Gwendolyn · CIK 0001791742 · President, Science & Tech.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,908

Underlying: Common Stock · 29,908 shares

Expires 2029-10-23

F3 · derivative.exercise_price: The exercise price of the option is $1.92 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period", through which the Reporting Person must remain in service to the Issuer, commenced on the Repricing Date and ends upon the earliest of (i) the one-year anniversary of the Repricing Date, (ii) a Sale Event (as defined in the 2018 Plan and 2019 Plan, as applicable) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2018 Plan and 2019 Plan, as applicable) due to the Reporting Person's death or disability.

F1 · kind: On May 15, 2025, the Issuer's board of directors approved an option repricing (the "Repricing"), to be effective May 19, 2025 (the "Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan (the "2018 Plan") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan (the "2019 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-074816 · ownership.xml · derivative · entry 3

Binder Gwendolyn · CIK 0001791742 · President, Science & Tech.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 29,908 shares

Expires 2029-10-23

F1 · kind: On May 15, 2025, the Issuer's board of directors approved an option repricing (the "Repricing"), to be effective May 19, 2025 (the "Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan (the "2018 Plan") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan (the "2019 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-074816 · ownership.xml · derivative · entry 2

Binder Gwendolyn · CIK 0001791742 · President, Science & Tech.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,667

Underlying: Common Stock · 66,667 shares

Expires 2029-08-21

F3 · derivative.exercise_price: The exercise price of the option is $1.92 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The "Retention Period", through which the Reporting Person must remain in service to the Issuer, commenced on the Repricing Date and ends upon the earliest of (i) the one-year anniversary of the Repricing Date, (ii) a Sale Event (as defined in the 2018 Plan and 2019 Plan, as applicable) and (iii) the termination of the Reporting Person's Service Relationship (as defined in the 2018 Plan and 2019 Plan, as applicable) due to the Reporting Person's death or disability.

F1 · kind: On May 15, 2025, the Issuer's board of directors approved an option repricing (the "Repricing"), to be effective May 19, 2025 (the "Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan (the "2018 Plan") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan (the "2019 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-074816 · ownership.xml · derivative · entry 1

Binder Gwendolyn · CIK 0001791742 · President, Science & Tech.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 66,667 shares

Expires 2029-08-21

F1 · kind: On May 15, 2025, the Issuer's board of directors approved an option repricing (the "Repricing"), to be effective May 19, 2025 (the "Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Cabaletta Bio, Inc. 2018 Stock Option and Incentive Plan (the "2018 Plan") or the Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan (the "2019 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-032326 · ownership.xml · derivative · entry 1

Binder Gwendolyn · CIK 0001791742 · President, Science & Tech.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,000

Underlying: Common Stock · 145,000 shares

Expires 2035-03-02

F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on March 3, 2026, with the remainder vesting in twelve substantially equal quarterly installments thereafter, subject to the reporting person's continued service on each such vesting date.

SEC source: 0001789769-24-000066 · wk-form4_1718312563.xml · derivative · entry 1

Binder Gwendolyn · CIK 0001791742 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2034-06-12

F1 · derivative.exercise_date: The option will vest in 12 substantially equal monthly installments commencing on July 13, 2024, subject to the Reporting Person's Continuous Service (as defined in the company's 2021 Equity Incentive Plan, the "Plan") through the vesting dates. Any portion of the option not vested on the date of the next annual stockholder meeting will vest in full, subject to the Reporting Person's Continuous Service through such date. The option will also vest in full in the event of the Reporting Person's death, Disability (as defined in the Plan) or upon a Change in Control (as defined in the Plan).

SEC source: 0000950170-24-024978 · ownership.xml · derivative · entry 1

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2034-02-28

F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on March 1, 2025, with the remainder vesting in twelve substantially equal quarterly installments thereafter, subject to the reporting person's continued service on each such vesting date.

SEC source: 0000950170-24-005888 · ownership.xml · derivative · entry 4

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,756

Underlying: Common Stock · 11,000 shares

Expires 2028-10-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F4 · derivative.exercise_date: This option vests over four years, with 25% vested on October 11, 2019, and the remaining shares vesting in 12 equal quarterly installments thereafter.

SEC source: 0000950170-24-005888 · ownership.xml · nonDerivative · entry 3

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 - $20.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-24-005888 · ownership.xml · nonDerivative · entry 2

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,700

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.16 - $20.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-24-005888 · ownership.xml · nonDerivative · entry 1

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

SEC source: 0000950170-23-071689 · ownership.xml · derivative · entry 4

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,756

Underlying: Common Stock · 11,000 shares

Expires 2028-10-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F4 · derivative.exercise_date: This option vests over four years, with 25% vested on October 11, 2019, and the remaining shares vesting in 12 equal quarterly installments thereafter.

SEC source: 0000950170-23-071689 · ownership.xml · nonDerivative · entry 3

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.06 - $22.40. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-23-071689 · ownership.xml · nonDerivative · entry 2

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,132

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.05 - $22.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-23-071689 · ownership.xml · nonDerivative · entry 1

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

SEC source: 0000950170-23-065521 · ownership.xml · derivative · entry 4

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,756

Underlying: Common Stock · 11,000 shares

Expires 2028-10-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F4 · derivative.exercise_date: This option vests over four years, with 25% vested on October 11, 2019, and the remaining shares vesting in 12 equal quarterly installments thereafter.

SEC source: 0000950170-23-065521 · ownership.xml · nonDerivative · entry 3

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.90 - $18.24. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-23-065521 · ownership.xml · nonDerivative · entry 2

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,458

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.90 - $17.89. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-23-065521 · ownership.xml · nonDerivative · entry 1

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

SEC source: 0000950170-23-054234 · ownership.xml · derivative · entry 4

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,756

Underlying: Common Stock · 11,000 shares

Expires 2028-10-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F4 · derivative.exercise_date: This option vests over four years, with 25% vested on October 11, 2019, and the remaining shares vesting in 12 equal quarterly installments thereafter.

SEC source: 0000950170-23-054234 · ownership.xml · nonDerivative · entry 3

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.15 - $14.54. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-23-054234 · ownership.xml · nonDerivative · entry 2

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,408

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.01 - $13.59. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-23-054234 · ownership.xml · nonDerivative · entry 1

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

SEC source: 0000950170-23-049005 · ownership.xml · derivative · entry 4

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 144,756

Underlying: Common Stock · 11,000 shares

Expires 2028-10-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F4 · derivative.exercise_date: This option vests over four years, with 25% vested on October 11, 2019, and the remaining shares vesting in 12 equal quarterly installments thereafter.

SEC source: 0000950170-23-049005 · ownership.xml · nonDerivative · entry 3

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,000

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.29 - $18.68. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-23-049005 · ownership.xml · nonDerivative · entry 2

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,700

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.17 - $18.11. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-23-049005 · ownership.xml · nonDerivative · entry 1

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

SEC source: 0000950170-23-043920 · ownership.xml · derivative · entry 4

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 155,756

Underlying: Common Stock · 11,000 shares

Expires 2028-10-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F4 · derivative.exercise_date: This option vests over four years, with 25% vested on October 11, 2019, and the remaining shares vesting in 12 equal quarterly installments thereafter.

SEC source: 0000950170-23-043920 · ownership.xml · nonDerivative · entry 3

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,000

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.7800 - $14.7799. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-23-043920 · ownership.xml · nonDerivative · entry 2

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,300

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.7800 - $13.7799. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000950170-23-043920 · ownership.xml · nonDerivative · entry 1

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

SEC source: 0000899243-23-017452 · doc4.xml · derivative · entry 4

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 166,756

Underlying: Common Stock · 11,000 shares

Expires 2028-10-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F4 · derivative.exercise_date: This option vests over four years, with 25% vested on October 11, 2019, and the remaining shares vesting in 12 equal quarterly installments thereafter.

SEC source: 0000899243-23-017452 · doc4.xml · nonDerivative · entry 3

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,000

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.17 - $14.42. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-23-017452 · doc4.xml · nonDerivative · entry 2

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,815

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.17 - $14.14. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-23-017452 · doc4.xml · nonDerivative · entry 1

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

SEC source: 0000899243-23-016147 · doc4.xml · derivative · entry 3

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 177,756

Underlying: Common Stock · 11,000 shares

Expires 2028-10-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F3 · derivative.exercise_date: This option vests over four years, with 25% vested on October 11, 2019, and the remaining shares vesting in 12 equal quarterly installments thereafter.

SEC source: 0000899243-23-016147 · doc4.xml · nonDerivative · entry 2

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,000

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.36 - $13.30. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000899243-23-016147 · doc4.xml · nonDerivative · entry 1

Binder Gwendolyn · CIK 0001791742 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.